Royalty Pharma (RPRX) Net Cash Flow (2019 - 2026)

Royalty Pharma has disclosed Net Cash Flow across 8 years of filings, most recently posting -$32.3 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$32.3 million, down 120.35% year-over-year; the trailing twelve-month figure through Mar 2026 was -$501.3 million (down 304.86% YoY), and the FY2025 annual result was -$310.3 million, down 168.65% from the prior year.
• Net Cash Flow came in at -$32.3 million for Q1 2026 at Royalty Pharma, up from -$320.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $921.6 million in Q2 2024 to a low of -$1.2 billion in Q3 2023.
• The 5-year median for Net Cash Flow is $158.7 million (2025), against an average of -$56.2 million.
• Across the five-year window, Net Cash Flow soared 376.84% in 2022 and plunged 1423.1% in 2025, its largest moves.
• Royalty Pharma's Net Cash Flow stood at $719.1 million in 2022, then sank by 163.89% to -$459.4 million in 2023, then soared by 95.42% to -$21.0 million in 2024, then slumped by 1423.1% to -$320.2 million in 2025, then jumped by 89.91% to -$32.3 million in 2026.
• The last three Net Cash Flow figures came in at -$32.3 million (Q1 2026), -$320.2 million (Q4 2025), and $307.0 million (Q3 2025), per Business Quant data.